Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon‐free treatment era
Open Access
- 11 August 2018
- journal article
- review article
- Published by Wiley in Immunological Reviews
- Vol. 285 (1) , 55-71
Abstract
Summary: The advent of powerful direct‐acting antiviral agents (DAAs) has revolutionized the treatment of hepatitis C. DAAs cure nearly all patients with short duration, oral treatments. Significant efforts are now underway to optimize DAA‐based treatments. We discuss the potential role of interferon in this optimization. Clinical studies present compelling evidence that DAAs perform better in treatment‐naive individuals than in individuals who previously failed treatment with interferon, a surprising correlation because interferon and DAAs are thought to act independently. Recent mathematical models explore a mechanistic hypothesis underlying this correlation. The hypothesis invokes the action of interferon at the cellular, individual, and population levels. Strong interferon responses prevent the productive infection of cells, reduce viral replication, and impede the development of resistance to DAAs in infected individuals and improve cure rates elicited by DAAs in treated populations. The models develop descriptions of these processes, integrate them into a comprehensive framework, and capture clinical data quantitatively, providing a successful test of the hypothesis. Individuals with strong endogenous interferon responses thus present a promising subpopulation for reducing DAA treatment durations. This review discusses the conceptual advances made by the models, highlights the new insights they unravel, and examines their applicability to optimize DAA‐based treatments.Keywords
This publication has 156 references indexed in Scilit:
- Multi‐layered stochasticity and paracrine signal propagation shape the type‐I interferon responseMolecular Systems Biology, 2012
- Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination With Other Hepatitis C Virus AntiviralsThe Journal of Infectious Diseases, 2012
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5AHepatology, 2011
- A diverse range of gene products are effectors of the type I interferon antiviral responseNature, 2011
- Hepatitis C Virus Blocks Interferon Effector Function by Inducing Protein Kinase R PhosphorylationCell Host & Microbe, 2009
- Interferon signaling and treatment outcome in chronic hepatitis CProceedings of the National Academy of Sciences, 2008
- Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment responseHepatology, 2007
- Activation of PKR: an open and shut case?Trends in Biochemical Sciences, 2007
- Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanismsProceedings of the National Academy of Sciences, 2006